Barry, Peter Walter, Kelley, Kate, Tan, Toni et al. · Journal of neurology, neurosurgery, and psychiatry · 2024 · DOI
In 2021, NICE (the UK's health guideline organization) published official recommendations for diagnosing and treating ME/CFS based on careful review of available research. When critics raised concerns about how the evidence was interpreted, the guideline authors explained that these criticisms were based on misunderstandings of how the guideline process works. This paper defends the guideline as a balanced and thoughtful approach to managing this serious condition.
This paper is important because NICE guidelines directly influence clinical practice and access to services across the UK healthcare system. By clarifying the evidence base and reasoning behind ME/CFS recommendations, it helps ensure that patients receive appropriate care and that clinicians have reliable guidance for this poorly understood condition.
This paper does not present new clinical data or research findings about ME/CFS itself. It is a methodological defense of guideline development processes rather than a study establishing new treatments, diagnostic markers, or disease mechanisms. It does not resolve ongoing scientific debates about ME/CFS etiology or optimal management strategies.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →